Eaton Vance Management boosted its position in shares of Stryker Co. (NYSE:SYK) by 0.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 605,140 shares of the medical technology company’s stock after purchasing an additional 4,838 shares during the quarter. Eaton Vance Management’s holdings in Stryker were worth $93,700,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Brown Advisory Securities LLC increased its holdings in Stryker by 8.1% during the 4th quarter. Brown Advisory Securities LLC now owns 13,792 shares of the medical technology company’s stock worth $2,134,000 after purchasing an additional 1,036 shares during the period. First Republic Investment Management Inc. increased its holdings in Stryker by 14.0% during the 4th quarter. First Republic Investment Management Inc. now owns 86,784 shares of the medical technology company’s stock worth $13,438,000 after purchasing an additional 10,659 shares during the period. Birch Hill Investment Advisors LLC purchased a new position in Stryker during the 4th quarter worth $213,000. Baird Financial Group Inc. increased its holdings in Stryker by 1.1% during the 4th quarter. Baird Financial Group Inc. now owns 82,319 shares of the medical technology company’s stock worth $12,746,000 after purchasing an additional 902 shares during the period. Finally, Norinchukin Bank The increased its holdings in Stryker by 7.5% during the 4th quarter. Norinchukin Bank The now owns 25,732 shares of the medical technology company’s stock worth $3,984,000 after purchasing an additional 1,787 shares during the period. Institutional investors own 74.49% of the company’s stock.
In related news, insider Graham A. Mclean sold 2,984 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $160.53, for a total transaction of $479,021.52. Following the transaction, the insider now directly owns 9,100 shares in the company, valued at approximately $1,460,823. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total value of $1,214,266.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,840 shares of company stock worth $2,749,989. 7.40% of the stock is owned by company insiders.
Stryker Co. (NYSE:SYK) opened at $158.96 on Friday. Stryker Co. has a fifty-two week low of $127.01 and a fifty-two week high of $170.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The stock has a market capitalization of $59,148.48, a price-to-earnings ratio of 59.31, a PEG ratio of 2.27 and a beta of 0.70.
Stryker (NYSE:SYK) last announced its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the business earned $1.78 EPS. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. sell-side analysts anticipate that Stryker Co. will post 7.12 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Wednesday, March 28th. This represents a $1.88 annualized dividend and a yield of 1.18%. Stryker’s dividend payout ratio (DPR) is 70.15%.
Several research analysts have commented on the company. Oppenheimer restated a “hold” rating and set a $165.00 price objective on shares of Stryker in a report on Thursday, February 1st. Citigroup restated a “market perform” rating and set a $165.00 price objective (up from $156.00) on shares of Stryker in a report on Thursday, February 1st. They noted that the move was a valuation call. Guggenheim restated a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Piper Jaffray Companies restated a “buy” rating and set a $170.00 price objective on shares of Stryker in a report on Wednesday, January 31st. Finally, Cantor Fitzgerald restated a “hold” rating and set a $163.00 price objective on shares of Stryker in a report on Tuesday, January 30th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $162.50.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/23/eaton-vance-management-grows-holdings-in-stryker-co-syk.html.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.